Adenocarcinoma of the Extrahepatic Bile Duct Completed Phase 2 Trials for Bortezomib (DB00188)

IndicationStatusPhase
DBCOND0030457 (Adenocarcinoma of the Extrahepatic Bile Duct)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00085410Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or GallbladderTreatment